Kansas House Bill HB2218

Kansas 2025-2026 Regular Session

• Introduced: 2/3/25
• Refer: 2/3/25
• Report Pass: 1/28/26

Caption

Amending the definition of "psilocybin" in the uniform controlled substances act to exclude the pharmaceutical composition of crystalline polymorph psilocybin and adding crystalline polymorph psilocybin to schedule IV of the uniformed controlled substance act.

Summary

HB 2218 amends Kansas’s Uniform Controlled Substances Act to carve out a specific pharmaceutical form of psilocybin from the general definition of “psilocybin.” The bill states that “psilocybin” does not include the pharmaceutical composition of crystalline polymorph psilocybin, identified in the text as COMP 360 or any FDA-approved trade name. It also adds that pharmaceutical composition to Schedule IV, which places it among controlled substances recognized under Kansas law but in a less restrictive category than higher schedules. The bill is structured to take effect only after federal approval of the pharmaceutical product. If the U.S. Food and Drug Administration approves the crystalline polymorph psilocybin drug product, the Kansas attorney general must certify that approval to the secretary of state within seven days, and the secretary of state must publish the certification in the Kansas Register. At that point, the amended definitions and Schedule IV listing become operative, and the prior versions of the affected statutes are repealed.

Impact

HB 2218 would directly amend K.S.A. 2024 Supp. 65-4101 and 65-4111, changing how Kansas law classifies psilocybin-related substances. The practical effect is to distinguish an FDA-approved pharmaceutical psilocybin product from other psilocybin substances, while still regulating that product as a Schedule IV controlled substance. This would affect controlled-substance enforcement, pharmacy and prescribing rules, and any regulated handling of the approved drug product once federal approval occurs.

Sentiment

The available record shows no committee transcript, vote tally, or recorded floor debate, so there is no documented public opposition or support in the provided materials. Based on the bill’s sponsor request from Compass Pathways and its technical, drug-scheduling focus, the measure appears to be a targeted regulatory bill rather than a broad policy overhaul. The absence of recorded votes or discussion prevents a stronger assessment of legislative sentiment.

Contention

The main policy issue is the treatment of psilocybin in a medical/pharmaceutical context versus its status as a controlled hallucinogenic substance. Supporters would likely view the bill as creating a pathway for an FDA-approved psilocybin medicine to be recognized under state law, while maintaining control through Schedule IV placement. Potential concerns could come from lawmakers or stakeholders wary of any loosening around psilocybin, even in pharmaceutical form, or from those questioning whether state scheduling should anticipate a future federal approval. No specific objections are documented in the provided record.